Streetbeat News

RNA

Avidity Biosciences, Inc.

https://www.aviditybiosciences.com

Industry

Biotechnology

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Open

33.61

Mkt cap

3.9B

Volume

1.5M

High

34.78

P/E Ratio

-11.28

52-wk high

56.00

Low

32.07

Div yield

N/A

52-wk low

7.88

Avidity Biosciences has made significant progress with its AOC platform, which targets genetic diseases by combining monoclonal antibodies with oligonucleotide therapies. The FDA has cleared Del-desiran (AOC 1001) for DM1, allowing it to progress to Phase 3 trials, and Del-brax (AOC 1020) for FSHD has shown promising results in reducing DUX4 gene expression.

Portfolio Pulse from

December 11, 2024 | 2:45 pm

Avidity Biosciences, a biopharmaceutical company, will participate in the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024. The company focuses on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™).

Portfolio Pulse from

November 26, 2024 | 3:15 pm

Avidity Biosciences' stock reached a record high as the company announced its expansion into the cardiac disease space with two new drugs targeting rare genetic cardiomyopathies.

Portfolio Pulse from

November 14, 2024 | 3:00 pm

Avidity Biosciences, Inc. (RNA) reported a Q3 loss of $0.65 per share, which was better than the Zacks Consensus Estimate of a $0.79 loss. However, the company lagged in revenue estimates.

Portfolio Pulse from

November 08, 2024 | 12:30 am

Avidity Biosciences reported its Q3 2024 financial results, highlighting progress in its clinical trials for rare diseases. The company is on track with its Phase 3 HARBOR study for DM1, initiated a biomarker cohort for the FORTITUDE study for FSHD, and reported positive data from the EXPLORE44 trial for DMD44. Avidity will also showcase its precision cardiology candidates and next-gen technology on November 12, 2024.

Portfolio Pulse from

November 07, 2024 | 9:15 pm

Analysts predict Avidity Biosciences, Inc. (RNA) will report a decline in earnings, lacking the key factors for an earnings beat in its upcoming report.

Portfolio Pulse from

November 06, 2024 | 4:30 pm

Needham analyst Joseph Stringer has reiterated a Buy rating on Avidity Biosciences (NASDAQ:RNA) and maintained a $60 price target.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 9:32 am

Chardan Capital analyst Keay Nakae maintains a Buy rating on Avidity Biosciences and raises the price target from $60 to $65.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:27 pm

Avidity Biosciences is advancing its FORTITUDE trial for delpacibart braxlosiran, targeting facioscapulohumeral muscular dystrophy, with a new biomarker cohort. The company aims for accelerated approval, with enrollment expected to complete by 1H 2025.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:11 pm

Analysts have varied opinions on Avidity Biosciences (NASDAQ:RNA), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $71.5, indicating positive expectations. Despite this, the company faces financial challenges, including declining revenue and low profitability metrics.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 9:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.